gip/glp-1 agonists The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Dual GIP/GLP-1 receptor agonists: New

The FDA has issued warnings about unapproved GLP-1 drugs circulating online - counterfeit, compounded, or mislabeled as research use only. When access to legitimate GLP-1 clinical trials is limited - by geography, logistics, or site capacity - progress slows

Emerging applications include non-alcoholic fatty liver disease and neurodegenerative conditions

Despite having fasted for 18 hr, and differing from the findings of prior procedures, endoscopy revealed substantial gastric content, which was suctioned before endotracheal intubation

With so many people interested in using GLP-1 agonists off-label to lose a few extra pounds, what does it mean for this class of drugs?

Background In idiopathic intracranial hypertension (IIH), sustained weight loss is the main pillar in modifying disease course, whereby glucagon-like peptide-1 receptor agonists (GLP-1-RAs) could present an attractive treatment option

FINALLY an advanced blend of plant extracts scientifically shown to promote GLP-1 production & reduce cravings, appetite & visceral fat with healthy diet & exercise.